Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug
Simcere Pharmaceutical Group Ltd (HKG: 2096) announced it has received a USD 40 million near‑term milestone payment from...
AbbVie
AbbVie Files Rinvoq for Vitiligo Approval in US and EU
AbbVie (NYSE: ABBV) announced it has submitted new indication applications to the U.S. Food and Drug...
AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
AbbVie Inc. (NYSE: ABBV) announced that China’s National Medical Products Administration (NMPA) has approved Risankizumab (SKYRIZI)...
AbbVie Commits $100 Billion US Investment and TrumpRx Expansion for Tariff Relief
AbbVie Inc. (NYSE: ABBV) announced a voluntary agreement with the Trump administration to advance drug access...
RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones
RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced an exclusive licensing agreement with AbbVie Inc. (NYSE: ABBV) for...
Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced a strategic collaboration and licensing option agreement...
AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China
AbbVie (NYSE: ABBV) announced that Rinvoq (upadacitinib) has been included in the priority review list...
AbbVie to End 11‑Year R&D Alliance with Alphabet‑Owned Calico Labs
AbbVie Inc. (NYSE: ABBV) announced today that it will terminate its long‑standing collaboration agreement with...
AbbVie Posts 8.4% Revenue Gain in Q3 2025, EPS Slumps on IPR&D Charges
U.S. biopharma leader AbbVie Inc. (NYSE: ABBV) released its third‑quarter fiscal‑2025 results. Net revenues rose...
AbbVie’s SELECT‑SWITCH Study Confirms Upadacitinib Outperforms Adalimumab in RA
AbbVie (NYSE: ABBV) announced positive topline data from its Phase IIIb/IV head‑to‑head trial, SELECT‑SWITCH, comparing upadacitinib...
BeOne Medicines Terminates Patent Dispute with AbbVie’s Pharmacyclics Over BTK Inhibitors
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that it has terminated...
Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products...
AbbVie Secures NMPA Priority Review for Epcoritamab in Relapsed Follicular Lymphoma
American pharmaceutical giant AbbVie (NYSE: ABBV) disclosed that its bispecific T‑cell engager, epcoritamab, has been...
AbbVie Acquires Bretisilocin from Gilgamesh in $1.2B Deal for MDD Treatment
American pharmaceutical giant AbbVie (NYSE: ABBV) has finalized a definitive agreement to acquire bretisilocin, an...
AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth
US-based multinational AbbVie Inc. (NYSE: ABBV) reported strong Q2 2025 results with global revenues increasing...
AbbVie Licenses IGI Therapeutics’ ISB 2001 for Oncology and Autoimmune Diseases
US-based AbbVie (NYSE: ABBV) this week announced a licensing agreement with IGI Therapeutics SA, a...
Guangdong Taienkang Submits Marketing Application for Generic Vuity to China’s NMPA
China-based Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced the submission of a marketing approval...
AbbVie’s Venclexta Approved by China’s NMPA for CLL/SLL Patients with 17p Deletion
US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China’s...
AbbVie to Acquire Capstan Therapeutics for Its First-in-Class CAR-T Candidate
US-based pharmaceutical giant AbbVie (NYSE: ABBV) is poised to acquire fellow American firm Capstan Therapeutics,...
Simcere Zaiming Initiates US Phase I Study of SIM0500 for Relapsed/Refractory Multiple Myeloma
China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming announced the first patient dosing...